... Any
manufacturer,
importer, or where
relevant downstream user, may, whilst retaining
full responsibility for complying with his
obligations under this
Regulation, appoint a
third party representative for all
proceedings under
Article 11,
Article 19, Title III and
Article 53 involving
discussions with other
manufacturers,
importers, or where
relevant downstream users. In these
cases, the
identity of a
manufacturer or
importer or
downstream user who has appointed a
representative shall not normally be disclosed by the
Agency to other
manufacturers,
importers, or, where
relevant,
downstream users. ...
... Any
manufacturer,
importer, or where
relevant downstream user, may, whilst retaining
full responsibility for complying with his
obligations under this
Regulation, appoint a
third party representative for all
proceedings under
Article 11,
Article 19, Title III and
Article 53 involving
discussions with other
manufacturers,
importers, or where
relevant downstream users. In these
cases, the
identity of a
manufacturer or
importer or
downstream user who has appointed a
representative shall not normally be disclosed by the
Agency to other
manufacturers,
importers, or, where
relevant,
downstream users. ...
... Any
manufacturer,
importer, or where
relevant downstream user, may, whilst retaining
full responsibility for complying with his
obligations under this
Regulation, appoint a
third party representative for all
proceedings under
Article 11,
Article 19, Title III and
Article 53 involving
discussions with other
manufacturers,
importers, or where
relevant downstream users. In these
cases, the
identity of a
manufacturer or
importer or
downstream user who has appointed a
representative shall not normally be disclosed by the
Agency to other
manufacturers,
importers, or, where
relevant,
downstream users. ...
ARTICLE-6: General obligation to register substances on their own or in preparations [
go to this ARTICLE]
ARTICLE-7: Registration and notification of substances in articles [
go to this ARTICLE]
... (e) a brief
description of the use(s) of the
substance(s) in the
article as specified in section 3.5 of Annex VI and of the uses of the
article(s); (f) the
tonnage range of the
substance(s), such as 1-10 tonnes, 10-100 tonnes and so on. ...
... (e) a brief
description of the use(s) of the
substance(s) in the
article as specified in section 3.5 of Annex VI and of the uses of the
article(s); (f) the
tonnage range of the
substance(s), such as 1-10 tonnes, 10-100 tonnes and so on. ...
ARTICLE-8: Only representative of a non-Community manufacturer [
go to this ARTICLE]
ARTICLE-9: Exemption from the general obligation to register for product and process orientated research and development (PPORD) [
go to this ARTICLE]
ARTICLE-10: Information to be submitted for general registration purposes [
go to this ARTICLE]
ARTICLE-11: Joint submission of data by multiple registrants [
go to this ARTICLE]
... 3. A
registrant may submit the
information referred to in
Article 10(a)(iv), (vi), (vii) or (ix) separately if: ...
ARTICLE-12: Information to be submitted depending on tonnage [
go to this ARTICLE]
... 3. This
Article shall apply to
producers of
articles adapted as necessary. ...
ARTICLE-13: General requirements for generation of information on intrinsic properties of substances [
go to this ARTICLE]
... 2. These
methods shall be regularly reviewed and improved with a
view to reducing
testing on
vertebrate animals and the
number of
animals involved. The
Commission, following
consultation with
relevant stakeholders, shall, as soon as possible, make a
proposal, if appropriate, to
amend the
Commission Regulation on
test methods adopted in
accordance with the
procedure referred to in
Article 133(4), and the
Annexes of this
Regulation, if
relevant, so as to replace, reduce or refine
animal testing.
Amendments to that
Commission Regulation shall be
adopted in
accordance with the
procedure specified in paragraph 3 and
amendments to the
Annexes of this
Regulation shall be
adopted in
accordance with the
procedure referred to in
Article 131. ...
... 2. These
methods shall be regularly reviewed and improved with a
view to reducing
testing on
vertebrate animals and the
number of
animals involved. The
Commission, following
consultation with
relevant stakeholders, shall, as soon as possible, make a
proposal, if appropriate, to
amend the
Commission Regulation on
test methods adopted in
accordance with the
procedure referred to in
Article 133(4), and the
Annexes of this
Regulation, if
relevant, so as to replace, reduce or refine
animal testing.
Amendments to that
Commission Regulation shall be
adopted in
accordance with the
procedure specified in paragraph 3 and
amendments to the
Annexes of this
Regulation shall be
adopted in
accordance with the
procedure referred to in
Article 131. ...
ARTICLE-14: Chemical safety report and duty to apply and recommend risk reduction measures [
go to this ARTICLE]
... (a) the applicable
concentrations defined in the table of
Article 3(3) of Directive 1999/45/EC; ...
ARTICLE-15: Substances in plant protection and biocidal products [
go to this ARTICLE]
ARTICLE-16: Duties of the Commission, the Agency and registrants of substances regarded as being registered [
go to this ARTICLE]
ARTICLE-17: Registration of on-site isolated intermediates [
go to this ARTICLE]
ARTICLE-18: Registration of transported isolated intermediates [
go to this ARTICLE]
ARTICLE-19: Joint submission of data on isolated intermediates by multiple registrants [
go to this ARTICLE]
... 2. The
Agency shall
undertake a completeness check of each
registration in
order to ascertain that all the elements required under
Articles 10 and
12 or under
Articles 17 or
18, as well as the
registration fee referred to in
Article 6(4),
Article 7(1) and (5),
Article 17(2) or
Article 18(2), have been provided. The completeness check shall not
include an
assessment of the
quality or the adequacy of any
data or justifications submitted. The
Agency shall
undertake the completeness check within three
weeks of the submission
date, or within three
months of the
relevant deadline of
Article 23, as
regards registrations of
phase-in substances submitted in the course of the two-
month period immediately preceding that deadline. If a
registration is incomplete, the
Agency shall inform the
registrant, before
expiry of the three-
week or three-
month period referred to in the second subparagraph, as to what further
information is required in
order for the
registration to be complete, while setting a
reasonable deadline for this. The
registrant shall complete his
registration and submit it to the
Agency within the deadline set. The
Agency shall confirm the submission
date of the further
information to the
registrant. The
Agency shall perform a further completeness check, considering the further
information submitted. The
Agency shall
reject the
registration if the
registrant fails to complete his
registration within the deadline set. The
registration fee shall not be reimbursed in such
cases. ...
... 2. The
Agency shall
undertake a completeness check of each
registration in
order to ascertain that all the elements required under
Articles 10 and
12 or under
Articles 17 or
18, as well as the
registration fee referred to in
Article 6(4),
Article 7(1) and (5),
Article 17(2) or
Article 18(2), have been provided. The completeness check shall not
include an
assessment of the
quality or the adequacy of any
data or justifications submitted. The
Agency shall
undertake the completeness check within three
weeks of the submission
date, or within three
months of the
relevant deadline of
Article 23, as
regards registrations of
phase-in substances submitted in the course of the two-
month period immediately preceding that deadline. If a
registration is incomplete, the
Agency shall inform the
registrant, before
expiry of the three-
week or three-
month period referred to in the second subparagraph, as to what further
information is required in
order for the
registration to be complete, while setting a
reasonable deadline for this. The
registrant shall complete his
registration and submit it to the
Agency within the deadline set. The
Agency shall confirm the submission
date of the further
information to the
registrant. The
Agency shall perform a further completeness check, considering the further
information submitted. The
Agency shall
reject the
registration if the
registrant fails to complete his
registration within the deadline set. The
registration fee shall not be reimbursed in such
cases. ...
... 2. The
Agency shall
undertake a completeness check of each
registration in
order to ascertain that all the elements required under
Articles 10 and
12 or under
Articles 17 or
18, as well as the
registration fee referred to in
Article 6(4),
Article 7(1) and (5),
Article 17(2) or
Article 18(2), have been provided. The completeness check shall not
include an
assessment of the
quality or the adequacy of any
data or justifications submitted. The
Agency shall
undertake the completeness check within three
weeks of the submission
date, or within three
months of the
relevant deadline of
Article 23, as
regards registrations of
phase-in substances submitted in the course of the two-
month period immediately preceding that deadline. If a
registration is incomplete, the
Agency shall inform the
registrant, before
expiry of the three-
week or three-
month period referred to in the second subparagraph, as to what further
information is required in
order for the
registration to be complete, while setting a
reasonable deadline for this. The
registrant shall complete his
registration and submit it to the
Agency within the deadline set. The
Agency shall confirm the submission
date of the further
information to the
registrant. The
Agency shall perform a further completeness check, considering the further
information submitted. The
Agency shall
reject the
registration if the
registrant fails to complete his
registration within the deadline set. The
registration fee shall not be reimbursed in such
cases. ...
... 2. The
Agency shall
undertake a completeness check of each
registration in
order to ascertain that all the elements required under
Articles 10 and
12 or under
Articles 17 or
18, as well as the
registration fee referred to in
Article 6(4),
Article 7(1) and (5),
Article 17(2) or
Article 18(2), have been provided. The completeness check shall not
include an
assessment of the
quality or the adequacy of any
data or justifications submitted. The
Agency shall
undertake the completeness check within three
weeks of the submission
date, or within three
months of the
relevant deadline of
Article 23, as
regards registrations of
phase-in substances submitted in the course of the two-
month period immediately preceding that deadline. If a
registration is incomplete, the
Agency shall inform the
registrant, before
expiry of the three-
week or three-
month period referred to in the second subparagraph, as to what further
information is required in
order for the
registration to be complete, while setting a
reasonable deadline for this. The
registrant shall complete his
registration and submit it to the
Agency within the deadline set. The
Agency shall confirm the submission
date of the further
information to the
registrant. The
Agency shall perform a further completeness check, considering the further
information submitted. The
Agency shall
reject the
registration if the
registrant fails to complete his
registration within the deadline set. The
registration fee shall not be reimbursed in such
cases. ...
... 2. The
Agency shall
undertake a completeness check of each
registration in
order to ascertain that all the elements required under
Articles 10 and
12 or under
Articles 17 or
18, as well as the
registration fee referred to in
Article 6(4),
Article 7(1) and (5),
Article 17(2) or
Article 18(2), have been provided. The completeness check shall not
include an
assessment of the
quality or the adequacy of any
data or justifications submitted. The
Agency shall
undertake the completeness check within three
weeks of the submission
date, or within three
months of the
relevant deadline of
Article 23, as
regards registrations of
phase-in substances submitted in the course of the two-
month period immediately preceding that deadline. If a
registration is incomplete, the
Agency shall inform the
registrant, before
expiry of the three-
week or three-
month period referred to in the second subparagraph, as to what further
information is required in
order for the
registration to be complete, while setting a
reasonable deadline for this. The
registrant shall complete his
registration and submit it to the
Agency within the deadline set. The
Agency shall confirm the submission
date of the further
information to the
registrant. The
Agency shall perform a further completeness check, considering the further
information submitted. The
Agency shall
reject the
registration if the
registrant fails to complete his
registration within the deadline set. The
registration fee shall not be reimbursed in such
cases. ...
... 2. The
Agency shall
undertake a completeness check of each
registration in
order to ascertain that all the elements required under
Articles 10 and
12 or under
Articles 17 or
18, as well as the
registration fee referred to in
Article 6(4),
Article 7(1) and (5),
Article 17(2) or
Article 18(2), have been provided. The completeness check shall not
include an
assessment of the
quality or the adequacy of any
data or justifications submitted. The
Agency shall
undertake the completeness check within three
weeks of the submission
date, or within three
months of the
relevant deadline of
Article 23, as
regards registrations of
phase-in substances submitted in the course of the two-
month period immediately preceding that deadline. If a
registration is incomplete, the
Agency shall inform the
registrant, before
expiry of the three-
week or three-
month period referred to in the second subparagraph, as to what further
information is required in
order for the
registration to be complete, while setting a
reasonable deadline for this. The
registrant shall complete his
registration and submit it to the
Agency within the deadline set. The
Agency shall confirm the submission
date of the further
information to the
registrant. The
Agency shall perform a further completeness check, considering the further
information submitted. The
Agency shall
reject the
registration if the
registrant fails to complete his
registration within the deadline set. The
registration fee shall not be reimbursed in such
cases. ...
... 2. The
Agency shall
undertake a completeness check of each
registration in
order to ascertain that all the elements required under
Articles 10 and
12 or under
Articles 17 or
18, as well as the
registration fee referred to in
Article 6(4),
Article 7(1) and (5),
Article 17(2) or
Article 18(2), have been provided. The completeness check shall not
include an
assessment of the
quality or the adequacy of any
data or justifications submitted. The
Agency shall
undertake the completeness check within three
weeks of the submission
date, or within three
months of the
relevant deadline of
Article 23, as
regards registrations of
phase-in substances submitted in the course of the two-
month period immediately preceding that deadline. If a
registration is incomplete, the
Agency shall inform the
registrant, before
expiry of the three-
week or three-
month period referred to in the second subparagraph, as to what further
information is required in
order for the
registration to be complete, while setting a
reasonable deadline for this. The
registrant shall complete his
registration and submit it to the
Agency within the deadline set. The
Agency shall confirm the submission
date of the further
information to the
registrant. The
Agency shall perform a further completeness check, considering the further
information submitted. The
Agency shall
reject the
registration if the
registrant fails to complete his
registration within the deadline set. The
registration fee shall not be reimbursed in such
cases. ...
ARTICLE-21: Manufacturing and import of substances [
go to this ARTICLE]
... 1. A
registrant may start or
continue the
manufacture or
import of a
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date, without
prejudice to
Article 27(8). In the
case of registrations of
phase-in substances, such a
registrant may
continue the
manufacture or
import of the
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date or, if submitted within the two-
month period before the
relevant deadline of
Article 23, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
months from that deadline, without
prejudice to
Article 27(8). In the
case of an update of a
registration according to
Article 22 a
registrant may
continue the
manufacture or
import of the
substance, or the
production or
import of the
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the update
date, without
prejudice to
Article 27(8). ...
... 1. A
registrant may start or
continue the
manufacture or
import of a
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date, without
prejudice to
Article 27(8). In the
case of registrations of
phase-in substances, such a
registrant may
continue the
manufacture or
import of the
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date or, if submitted within the two-
month period before the
relevant deadline of
Article 23, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
months from that deadline, without
prejudice to
Article 27(8). In the
case of an update of a
registration according to
Article 22 a
registrant may
continue the
manufacture or
import of the
substance, or the
production or
import of the
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the update
date, without
prejudice to
Article 27(8). ...
... 1. A
registrant may start or
continue the
manufacture or
import of a
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date, without
prejudice to
Article 27(8). In the
case of registrations of
phase-in substances, such a
registrant may
continue the
manufacture or
import of the
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date or, if submitted within the two-
month period before the
relevant deadline of
Article 23, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
months from that deadline, without
prejudice to
Article 27(8). In the
case of an update of a
registration according to
Article 22 a
registrant may
continue the
manufacture or
import of the
substance, or the
production or
import of the
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the update
date, without
prejudice to
Article 27(8). ...
... 1. A
registrant may start or
continue the
manufacture or
import of a
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date, without
prejudice to
Article 27(8). In the
case of registrations of
phase-in substances, such a
registrant may
continue the
manufacture or
import of the
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date or, if submitted within the two-
month period before the
relevant deadline of
Article 23, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
months from that deadline, without
prejudice to
Article 27(8). In the
case of an update of a
registration according to
Article 22 a
registrant may
continue the
manufacture or
import of the
substance, or the
production or
import of the
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the update
date, without
prejudice to
Article 27(8). ...
... 1. A
registrant may start or
continue the
manufacture or
import of a
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date, without
prejudice to
Article 27(8). In the
case of registrations of
phase-in substances, such a
registrant may
continue the
manufacture or
import of the
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date or, if submitted within the two-
month period before the
relevant deadline of
Article 23, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
months from that deadline, without
prejudice to
Article 27(8). In the
case of an update of a
registration according to
Article 22 a
registrant may
continue the
manufacture or
import of the
substance, or the
production or
import of the
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the update
date, without
prejudice to
Article 27(8). ...
... 1. A
registrant may start or
continue the
manufacture or
import of a
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date, without
prejudice to
Article 27(8). In the
case of registrations of
phase-in substances, such a
registrant may
continue the
manufacture or
import of the
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date or, if submitted within the two-
month period before the
relevant deadline of
Article 23, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
months from that deadline, without
prejudice to
Article 27(8). In the
case of an update of a
registration according to
Article 22 a
registrant may
continue the
manufacture or
import of the
substance, or the
production or
import of the
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the update
date, without
prejudice to
Article 27(8). ...
... 1. A
registrant may start or
continue the
manufacture or
import of a
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date, without
prejudice to
Article 27(8). In the
case of registrations of
phase-in substances, such a
registrant may
continue the
manufacture or
import of the
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date or, if submitted within the two-
month period before the
relevant deadline of
Article 23, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
months from that deadline, without
prejudice to
Article 27(8). In the
case of an update of a
registration according to
Article 22 a
registrant may
continue the
manufacture or
import of the
substance, or the
production or
import of the
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the update
date, without
prejudice to
Article 27(8). ...
... 1. A
registrant may start or
continue the
manufacture or
import of a
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date, without
prejudice to
Article 27(8). In the
case of registrations of
phase-in substances, such a
registrant may
continue the
manufacture or
import of the
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date or, if submitted within the two-
month period before the
relevant deadline of
Article 23, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
months from that deadline, without
prejudice to
Article 27(8). In the
case of an update of a
registration according to
Article 22 a
registrant may
continue the
manufacture or
import of the
substance, or the
production or
import of the
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the update
date, without
prejudice to
Article 27(8). ...
... 1. A
registrant may start or
continue the
manufacture or
import of a
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date, without
prejudice to
Article 27(8). In the
case of registrations of
phase-in substances, such a
registrant may
continue the
manufacture or
import of the
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date or, if submitted within the two-
month period before the
relevant deadline of
Article 23, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
months from that deadline, without
prejudice to
Article 27(8). In the
case of an update of a
registration according to
Article 22 a
registrant may
continue the
manufacture or
import of the
substance, or the
production or
import of the
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the update
date, without
prejudice to
Article 27(8). ...
... 1. A
registrant may start or
continue the
manufacture or
import of a
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date, without
prejudice to
Article 27(8). In the
case of registrations of
phase-in substances, such a
registrant may
continue the
manufacture or
import of the
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date or, if submitted within the two-
month period before the
relevant deadline of
Article 23, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
months from that deadline, without
prejudice to
Article 27(8). In the
case of an update of a
registration according to
Article 22 a
registrant may
continue the
manufacture or
import of the
substance, or the
production or
import of the
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the update
date, without
prejudice to
Article 27(8). ...
... 1. A
registrant may start or
continue the
manufacture or
import of a
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date, without
prejudice to
Article 27(8). In the
case of registrations of
phase-in substances, such a
registrant may
continue the
manufacture or
import of the
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date or, if submitted within the two-
month period before the
relevant deadline of
Article 23, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
months from that deadline, without
prejudice to
Article 27(8). In the
case of an update of a
registration according to
Article 22 a
registrant may
continue the
manufacture or
import of the
substance, or the
production or
import of the
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the update
date, without
prejudice to
Article 27(8). ...
... 1. A
registrant may start or
continue the
manufacture or
import of a
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date, without
prejudice to
Article 27(8). In the
case of registrations of
phase-in substances, such a
registrant may
continue the
manufacture or
import of the
substance or
production or
import of an
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the submission
date or, if submitted within the two-
month period before the
relevant deadline of
Article 23, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
months from that deadline, without
prejudice to
Article 27(8). In the
case of an update of a
registration according to
Article 22 a
registrant may
continue the
manufacture or
import of the
substance, or the
production or
import of the
article, if there is no indication to the
contrary from the
Agency in
accordance with
Article 20(2) within the three
weeks after the update
date, without
prejudice to
Article 27(8). ...
ARTICLE-22: Further duties of registrants [
go to this ARTICLE]
... 3. The
Agency shall
undertake a completeness check according to
Article 20(2) first and second subparagraphs of each updated
registration. In
cases where the update is in
accordance with
Article 12(2) and with paragraph 1(c) of this
Article then the
Agency shall check the completeness of the
information supplied by the
registrant and
Article 20(2) shall apply adapted as necessary. ...
... 3. The
Agency shall
undertake a completeness check according to
Article 20(2) first and second subparagraphs of each updated
registration. In
cases where the update is in
accordance with
Article 12(2) and with paragraph 1(c) of this
Article then the
Agency shall check the completeness of the
information supplied by the
registrant and
Article 20(2) shall apply adapted as necessary. ...
... 3. The
Agency shall
undertake a completeness check according to
Article 20(2) first and second subparagraphs of each updated
registration. In
cases where the update is in
accordance with
Article 12(2) and with paragraph 1(c) of this
Article then the
Agency shall check the completeness of the
information supplied by the
registrant and
Article 20(2) shall apply adapted as necessary. ...
... 3. The
Agency shall
undertake a completeness check according to
Article 20(2) first and second subparagraphs of each updated
registration. In
cases where the update is in
accordance with
Article 12(2) and with paragraph 1(c) of this
Article then the
Agency shall check the completeness of the
information supplied by the
registrant and
Article 20(2) shall apply adapted as necessary. ...
... 4. In
cases covered by
Articles 11 or
19, each
registrant shall submit separately the
information specified in paragraph 1(c) of this
Article. ...
ARTICLE-23: Specific provisions for phase-in substances [
go to this ARTICLE]
... 1.
Article 5,
Article 6,
Article 7(1),
Article 17,
Article 18 and
Article 21 shall not apply until 1 December 2010 to the following
substances: ...
... 1.
Article 5,
Article 6,
Article 7(1),
Article 17,
Article 18 and
Article 21 shall not apply until 1 December 2010 to the following
substances: ...
... 1.
Article 5,
Article 6,
Article 7(1),
Article 17,
Article 18 and
Article 21 shall not apply until 1 December 2010 to the following
substances: ...
... 1.
Article 5,
Article 6,
Article 7(1),
Article 17,
Article 18 and
Article 21 shall not apply until 1 December 2010 to the following
substances: ...
... 1.
Article 5,
Article 6,
Article 7(1),
Article 17,
Article 18 and
Article 21 shall not apply until 1 December 2010 to the following
substances: ...
... 1.
Article 5,
Article 6,
Article 7(1),
Article 17,
Article 18 and
Article 21 shall not apply until 1 December 2010 to the following
substances: ...
ARTICLE-26: Duty to inquire prior to registration [
go to this ARTICLE]
ARTICLE-27: Sharing of existing data in the case of registered substances [
go to this ARTICLE]
ARTICLE-28: Duty to pre-register for phase-in substances [
go to this ARTICLE]
... 3.
Registrants who do not submit the
information required under paragraph 1 shall not be able to rely on
Article 23. ...
ARTICLE-29: Substance Information Exchange Fora [
go to this ARTICLE]
ARTICLE-30: Sharing of data involving tests [
go to this ARTICLE]
... 6. The
owner of the
study who has refused to provide either
proof of the
cost or the
study itself, as referred to in paragraph 3 or 4 of this
Article, shall be penalised in
accordance with
Article 126. ...
... 6. The
owner of the
study who has refused to provide either
proof of the
cost or the
study itself, as referred to in paragraph 3 or 4 of this
Article, shall be penalised in
accordance with
Article 126. ...
ARTICLE-31: Requirements for Safety Data Sheets [
go to this ARTICLE]
ARTICLE-32: Duty to communicate information down the supply chain for substances on their own or in preparations for which a safety
data sheet is not required [
go to this ARTICLE]
ARTICLE-33: Duty to communicate information on substances in articles [
go to this ARTICLE]
ARTICLE-35: Access to information for workers [
go to this ARTICLE]
ARTICLE-37: Downstream user chemical safety assessments and duty to identify, apply and recommend risk reduction measures [
go to this ARTICLE]
... 3. For
registered substances, the
manufacturer,
importer or
downstream user shall comply with the
obligations laid down in
Article 14 either before he next
supplies the
substance on its own or in a
preparation to the
downstream user making the
request referred to in paragraph 2 of this
Article, provided that the
request was made at least one
month before the
supply, or within one
month after the
request, whichever is the later. For
phase-in substances, the
manufacturer,
importer or
downstream user shall comply with this
request and with the
obligations laid down in
Article 14 before the
relevant deadline in
Article 23 has expired, provided that the
downstream user makes his
request at least 12
months before the deadline in
question. Where the
manufacturer,
importer or
downstream user, having assessed the use in
accordance with
Article 14, is
unable to
include it as an
identified use for
reasons of
protection of
human health or the
environment, he shall provide the
Agency and the
downstream user with the
reason(s) for that
decision in
writing without
delay and shall not
supply downstream user(s) with the
substance without
including these
reason(s) in the
information referred to under
Articles 31 or
32. The
manufacturer or
importer shall
include this use in section 3.7 of Annex VI in his update of the
registration in
accordance with
Article 22(1)(d). ...
... 3. For
registered substances, the
manufacturer,
importer or
downstream user shall comply with the
obligations laid down in
Article 14 either before he next
supplies the
substance on its own or in a
preparation to the
downstream user making the
request referred to in paragraph 2 of this
Article, provided that the
request was made at least one
month before the
supply, or within one
month after the
request, whichever is the later. For
phase-in substances, the
manufacturer,
importer or
downstream user shall comply with this
request and with the
obligations laid down in
Article 14 before the
relevant deadline in
Article 23 has expired, provided that the
downstream user makes his
request at least 12
months before the deadline in
question. Where the
manufacturer,
importer or
downstream user, having assessed the use in
accordance with
Article 14, is
unable to
include it as an
identified use for
reasons of
protection of
human health or the
environment, he shall provide the
Agency and the
downstream user with the
reason(s) for that
decision in
writing without
delay and shall not
supply downstream user(s) with the
substance without
including these
reason(s) in the
information referred to under
Articles 31 or
32. The
manufacturer or
importer shall
include this use in section 3.7 of Annex VI in his update of the
registration in
accordance with
Article 22(1)(d). ...
... 3. For
registered substances, the
manufacturer,
importer or
downstream user shall comply with the
obligations laid down in
Article 14 either before he next
supplies the
substance on its own or in a
preparation to the
downstream user making the
request referred to in paragraph 2 of this
Article, provided that the
request was made at least one
month before the
supply, or within one
month after the
request, whichever is the later. For
phase-in substances, the
manufacturer,
importer or
downstream user shall comply with this
request and with the
obligations laid down in
Article 14 before the
relevant deadline in
Article 23 has expired, provided that the
downstream user makes his
request at least 12
months before the deadline in
question. Where the
manufacturer,
importer or
downstream user, having assessed the use in
accordance with
Article 14, is
unable to
include it as an
identified use for
reasons of
protection of
human health or the
environment, he shall provide the
Agency and the
downstream user with the
reason(s) for that
decision in
writing without
delay and shall not
supply downstream user(s) with the
substance without
including these
reason(s) in the
information referred to under
Articles 31 or
32. The
manufacturer or
importer shall
include this use in section 3.7 of Annex VI in his update of the
registration in
accordance with
Article 22(1)(d). ...
... 3. For
registered substances, the
manufacturer,
importer or
downstream user shall comply with the
obligations laid down in
Article 14 either before he next
supplies the
substance on its own or in a
preparation to the
downstream user making the
request referred to in paragraph 2 of this
Article, provided that the
request was made at least one
month before the
supply, or within one
month after the
request, whichever is the later. For
phase-in substances, the
manufacturer,
importer or
downstream user shall comply with this
request and with the
obligations laid down in
Article 14 before the
relevant deadline in
Article 23 has expired, provided that the
downstream user makes his
request at least 12
months before the deadline in
question. Where the
manufacturer,
importer or
downstream user, having assessed the use in
accordance with
Article 14, is
unable to
include it as an
identified use for
reasons of
protection of
human health or the
environment, he shall provide the
Agency and the
downstream user with the
reason(s) for that
decision in
writing without
delay and shall not
supply downstream user(s) with the
substance without
including these
reason(s) in the
information referred to under
Articles 31 or
32. The
manufacturer or
importer shall
include this use in section 3.7 of Annex VI in his update of the
registration in
accordance with
Article 22(1)(d). ...
... 3. For
registered substances, the
manufacturer,
importer or
downstream user shall comply with the
obligations laid down in
Article 14 either before he next
supplies the
substance on its own or in a
preparation to the
downstream user making the
request referred to in paragraph 2 of this
Article, provided that the
request was made at least one
month before the
supply, or within one
month after the
request, whichever is the later. For
phase-in substances, the
manufacturer,
importer or
downstream user shall comply with this
request and with the
obligations laid down in
Article 14 before the
relevant deadline in
Article 23 has expired, provided that the
downstream user makes his
request at least 12
months before the deadline in
question. Where the
manufacturer,
importer or
downstream user, having assessed the use in
accordance with
Article 14, is
unable to
include it as an
identified use for
reasons of
protection of
human health or the
environment, he shall provide the
Agency and the
downstream user with the
reason(s) for that
decision in
writing without
delay and shall not
supply downstream user(s) with the
substance without
including these
reason(s) in the
information referred to under
Articles 31 or
32. The
manufacturer or
importer shall
include this use in section 3.7 of Annex VI in his update of the
registration in
accordance with
Article 22(1)(d). ...
... 3. For
registered substances, the
manufacturer,
importer or
downstream user shall comply with the
obligations laid down in
Article 14 either before he next
supplies the
substance on its own or in a
preparation to the
downstream user making the
request referred to in paragraph 2 of this
Article, provided that the
request was made at least one
month before the
supply, or within one
month after the
request, whichever is the later. For
phase-in substances, the
manufacturer,
importer or
downstream user shall comply with this
request and with the
obligations laid down in
Article 14 before the
relevant deadline in
Article 23 has expired, provided that the
downstream user makes his
request at least 12
months before the deadline in
question. Where the
manufacturer,
importer or
downstream user, having assessed the use in
accordance with
Article 14, is
unable to
include it as an
identified use for
reasons of
protection of
human health or the
environment, he shall provide the
Agency and the
downstream user with the
reason(s) for that
decision in
writing without
delay and shall not
supply downstream user(s) with the
substance without
including these
reason(s) in the
information referred to under
Articles 31 or
32. The
manufacturer or
importer shall
include this use in section 3.7 of Annex VI in his update of the
registration in
accordance with
Article 22(1)(d). ...
... 3. For
registered substances, the
manufacturer,
importer or
downstream user shall comply with the
obligations laid down in
Article 14 either before he next
supplies the
substance on its own or in a
preparation to the
downstream user making the
request referred to in paragraph 2 of this
Article, provided that the
request was made at least one
month before the
supply, or within one
month after the
request, whichever is the later. For
phase-in substances, the
manufacturer,
importer or
downstream user shall comply with this
request and with the
obligations laid down in
Article 14 before the
relevant deadline in
Article 23 has expired, provided that the
downstream user makes his
request at least 12
months before the deadline in
question. Where the
manufacturer,
importer or
downstream user, having assessed the use in
accordance with
Article 14, is
unable to
include it as an
identified use for
reasons of
protection of
human health or the
environment, he shall provide the
Agency and the
downstream user with the
reason(s) for that
decision in
writing without
delay and shall not
supply downstream user(s) with the
substance without
including these
reason(s) in the
information referred to under
Articles 31 or
32. The
manufacturer or
importer shall
include this use in section 3.7 of Annex VI in his update of the
registration in
accordance with
Article 22(1)(d). ...
ARTICLE-38: Obligation for downstream users to report information [
go to this ARTICLE]
ARTICLE-39: Application of downstream user obligations [
go to this ARTICLE]
ARTICLE-40: Examination of testing proposals [
go to this ARTICLE]
ARTICLE-41: Compliance check of registrations [
go to this ARTICLE]
... (d) that any explanation(s) submitted in
accordance with
Article 11(3) or
Article 19(2) have an
objective basis. ...
... (d) that any explanation(s) submitted in
accordance with
Article 11(3) or
Article 19(2) have an
objective basis. ...
... (a) the
dossier contains
information in
Article 10(a)(iv), (vi) and/or (vii) submitted separately as per
Article 11(3); or ...
... (a) the
dossier contains
information in
Article 10(a)(iv), (vi) and/or (vii) submitted separately as per
Article 11(3); or ...
ARTICLE-42: Check of information submitted and follow-up to dossier evaluation [
go to this ARTICLE]
ARTICLE-43: Procedure and time periods for examination of testing proposals [
go to this ARTICLE]
ARTICLE-44: Criteria for substance evaluation [
go to this ARTICLE]